Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Bio-Techne stock
Learn how to easily invest in Bio-Techne stock.
Bio-Techne is a biotechnology business based in the US. Bio-Techne shares (TECH) are listed on the NASDAQ and all prices are listed in US Dollars. Bio-Techne employs 3,000 staff and has a trailing 12-month revenue of around $1.1 billion.
How to buy Bio-Techne stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – TECH. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
- Commission-free trading
- Commission-free crypto
- No minimum account balance
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.
Bio-Techne stock price (NASDAQ: TECH)Use our graph to track the performance of TECH stocks over time.
Bio-Techne shares at a glance
|Latest market close||$79.83|
|52-week range||$67.68 - $113.06|
|50-day moving average||$83.24|
|200-day moving average||$85.74|
|Wall St. target price||$104.89|
|Dividend yield||$0.32 (0.4%)|
|Earnings per share (TTM)||$1.79|
Buy Bio-Techne stocks from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Bio-Techne stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Bio-Techne price performance over time
|1 week (2023-01-20)||-2.00%|
|1 month (2022-12-27)||-2.90%|
|3 months (2022-10-27)||-73.01%|
|6 months (2022-07-27)||-78.68%|
|1 year (2022-01-27)||-77.44%|
|2 years (2021-01-27)||-74.93%|
|3 years (2020-01-27)||216.79|
|5 years (2018-01-26)||142.32|
Is Bio-Techne stock undervalued or overvalued?
Valuing Bio-Techne stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bio-Techne's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Bio-Techne's P/E ratio
Bio-Techne's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 45x. In other words, Bio-Techne shares trade at around 45x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Bio-Techne's PEG ratio
Bio-Techne's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.1476. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bio-Techne's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Bio-Techne's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $358.5 million.
The EBITDA is a measure of a Bio-Techne's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$1.1 billion|
|Operating margin TTM||26.5%|
|Gross profit TTM||$758.1 million|
|Return on assets TTM||8.01%|
|Return on equity TTM||16.71%|
|Market capitalisation||$12.5 billion|
TTM: trailing 12 months
Bio-Techne share dividends
Dividend payout ratio: 28.43% of net profits
Recently Bio-Techne has paid out, on average, around 28.43% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.4% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Bio-Techne shareholders could enjoy a 0.4% return on their shares, in the form of dividend payments. In Bio-Techne's case, that would currently equate to about $0.32 per share.
While Bio-Techne's payout ratio might seem fairly standard, it's worth remembering that Bio-Techne may be investing much of the rest of its net profits in future growth.
Bio-Techne's most recent dividend payout was on 27 November 2022. The latest dividend was paid out to all shareholders who bought their shares by 9 November 2022 (the "ex-dividend date").
Have Bio-Techne's shares ever split?
Bio-Techne's shares were split on a 4:1 basis on 29 November 2022. So if you had owned 1 share the day before before the split, the next day you'd have owned 4 shares. This wouldn't directly have changed the overall worth of your Bio-Techne shares – just the quantity. However, indirectly, the new 75% lower share price could have impacted the market appetite for Bio-Techne shares which in turn could have impacted Bio-Techne's share price.
Bio-Techne share price volatility
Over the last 12 months, Bio-Techne's shares have ranged in value from as little as $67.675 up to $113.0563. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bio-Techne's is 1.2515. This would suggest that Bio-Techne's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014.
Bio-Techne in the news
BIO-TECHNE LAUNCHES THE MauriceFlex™ SYSTEM, ADDING cIEF FRACTIONATION CAPABILITY TO THE GOLD STANDARD MAURICE ASSAYS
BIO-TECHNE TO HOST CONFERENCE CALL ON FEBRUARY 2, 2023, TO ANNOUNCE SECOND QUARTER 2023 FINANCIAL RESULTS
BIO-TECHNE LAUNCHES RNASCOPE PLUS ASSAY TO ADVANCE GENE THERAPY DEVELOPMENT
Frequently asked questionsWhat percentage of Bio-Techne is owned by insiders or institutions?
Currently 0.881% of Bio-Techne shares are held by insiders and 97.795% by institutions. How many people work for Bio-Techne?
Latest data suggests 3,000 work at Bio-Techne. When does the fiscal year end for Bio-Techne?
Bio-Techne's fiscal year ends in June. Where is Bio-Techne based?
Bio-Techne's address is: 614 McKinley Place N.E., Minneapolis, MN, United States, 55413 What is Bio-Techne's ISIN number?
Bio-Techne's international securities identification number is: US09073M1045 What is Bio-Techne's CUSIP number?
Bio-Techne's Committee on Uniform Securities Identification Procedures number is: 878377100
More guides on Finder
How to buy TXO Energy (TXO) stock when it goes public
Everything we know about the TXO Energy IPO, plus information on how to buy in.
How to buy Brera (BREA) stock when it goes public
Everything we know about the Brera IPO, plus information on how to buy in.
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
How to research stocks
Learn about stock analysis and how to use it to find the right company to buy.
Ask an Expert